Developing a generic prolonged-release isosorbide-5-mononitrate tablet

Astimex, a pharmaceutical company focusing primarily on the Nordic market, wanted to extend their product line. Without access to internal development or manufacturing resources, the company was looking for a partner who could help them achieve their goals.

Recipharm was selected to develop and manufacture a new generic isosorbide- 5- mononitrate (5-ISMN) 30 mg prolonged-release tablet and assume responsibility for the subsequent commercial supply.

Register below to download the full Case study.
/sites/default/files/media/CaseStudy_Developing-a-generic-prolonged-release-isosorbide-5-mononitrate-tablet.pdf
False
True